Claims for Patent: 9,931,400

Summary for Patent: 9,931,400

Title:	Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
Abstract:	Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient.
Inventor(s):	Jeong; Yun Ju (Anyang-si, KR), Kim; Kyung Ah (Seongnam-si, KR), Song; Yun Jeong (Seongnam-si, KR), Lee; Ji Min (Seoul, KR), Lee; Hyo Seon (Hwaseong-si, KR), Choi; Jae Hyun (Seongnam-si, KR), Lee; Saet Byoul (Seoul, KR)
Assignee:	SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)
Application Number:	14/025,403
Patent Claims:	1. A method for treatment of cancer metastasis, the method comprising co-administering (a) a VEGF antagonist and (b) an anti-c-Met antibody or antigen-binding fragment thereof to a subject in need thereof, wherein the anti-c-Met antibody or the antigen-binding fragment thereof comprises: a heavy chain variable region comprising a complementarity determining region (CDR)-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 22, 23, and 24; a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 25, and 26; and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 27, and 28; and a light chain variable region comprising a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 29, 30, 31, 32, 33, and 106, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 34, 35, and 36, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 13, 14, 15, 16, and 37. 2. The method of claim 1, wherein the angiogenesis inhibitor and the anti-c-Met antibody are administered simultaneously or sequentially in any order. 3. The method according to claim 1, wherein the VEGF antagonist comprises at least one selected from the group consisting of bevacizumab, VEGF-trap, sunitinib, sunitinib malate, AEE-788, axitinib, AG-028262, combretastatin A4 analog, cediranib, BMS-387032, CEP-7055, CHIR-258, CP-547632, CP-564959, E-7080, Pazopanib, GW-654652, indazolylpyrimidine Kdr inhibitors, KRN-951, quinoline-urea VEGF inhibitors, midostaurin, vatalanib, anilinophthalazine derivative VEGF inhibitors, semaxanib, SU-6668, thalidomide, XL-647, XL-999, vandetanib, anilinoquinazoline VEGF inhibitors, ZK-304709, indirubin derivative VEGF inhibitors, CDP791, Enzastaurin, BIBF 1120, BAY 573952, BAY 734506, XL 184, IMC-1121B, CEP 701, SU 014813, SU 10944, SU 12662, OSI-930, BMS 582664, N-acetylcolchinol phosphate, ANG-400 series drugs, Imatinib, everolimus, and dasatinib. 4. The method according to claim 1, wherein the anti c-Met antibody or the antigen-binding fragment thereof specifically binds to an epitope consisting of the amino acid sequence of SEQ ID NO: 71, 72, or 73. 5. The method according to claim 1, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 17, 74, 87, 90, 91, 92, 93, and 94, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 18, 19, 20, 21, 75, 88, 95, 96, 97, 98, 99, 107, and 132. 6. The method according to claim 1, wherein the anti c-Met antibody comprises: a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, the amino acid sequence from the 18.sup.th to 462.sup.nd positions of SEQ ID NO: 62, the amino acid sequence from the 18.sup.th to 461.sup.st positions of SEQ ID NO: 64, and the amino acid sequence from the 18.sup.th to 460.sup.th positions of SEQ ID NO: 66, and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 108, the amino acid sequence from the 21.sup.st to 240.sup.th positions of SEQ ID NO: 68, and the amino acid sequence from the 21.sup.st to 240.sup.th positions of SEQ ID NO: 70. 7. The method according to claim 6, wherein the anti c-Met antibody comprises: a heavy chain comprising the amino acid sequence from the 18.sup.th to 460.sup.th positions of SEQ ID NO: 66, and a light chain comprising the amino acid sequence from the 21.sup.st to 240.sup.th positions of SEQ ID NO: 68. 8. The method according to claim 1, wherein the anti c-Met antibody is monoclonal. 9. The method according to claim 1, wherein the anti c-Met antibody is an antibody of mouse origin, a mouse-human chimeric antibody, or a humanized antibody. 10. The method according to claim 1, wherein the antigen-binding fragment is selected from the group consisting of scFv, (scFv).sub.2, Fab, Fab', and F(ab').sub.2.

Details for Patent 9,931,400

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-09-12